my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Wyeth improves the lives of millions of people around the world with its outstanding products. And new, innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines and biotechnology, Wyeth is exploring more than 60 new therapies for medical more
Wyeth improves the lives of millions of people around the world with its outstanding products. And new, innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines and biotechnology, Wyeth is exploring more than 60 new therapies for medical more
Wyeth improves the lives of millions of people around the world with its outstanding products. And new, innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines and biotechnology, Wyeth is exploring more than 60 new therapies for medical more
PolyTherics Limited announced the appointment of Dr John Burt as Chief Business Officer. John has broad business and corporate development experience and was previously CEO of Thiakis, a company which he co-founded with Professor Steve Bloom of Imperial College in 2004 and sold to Wyeth in 2008. more
Ablynx announced that it is now eligible for a milestone payment of $3 million as a result of the initiation by Pfizer of a new Phase I clinical study in healthy volunteers for a second Nanobody (PF-05230905) targeting tumour necrosis factor alpha (TNF-alpha). Pfizer's lead anti-TNF-alpha Nanobody more
biocrea GmbH announced further details about the newly incorporated company and its strategy going forward. biocrea acquires the CNS pipeline and phosphodiesterase enzyme (PDE) inhibitor platform from Biotie Therapies Corp. The new company will be based in Radebeul, Germany. Dr. Thomas Kronbach, Bi more
Aparna Singh (AS), Program Manager with Frost & Sullivan's Chemical Materials and Foods team caught up with Dr. Michael Kolb (Dr. MK) at Frost & Sullivan's Opportunities in Lifescience Molecules: Global Partnership Summit 2006. This annual summit was held at Goa (India) from 21st -23rd May, 2006. more
Bioterrorism poses a daunting challenge to global security and public health in the 21st century. Variola major virus, the etiological agent of smallpox, and Bacillus anthracis, the bacterial pathogen responsible for anthrax, remain at the apex of potential pathogens that could be used in a bioterr more
Jim connolly Nature Reviews Drug Discovery 9, 674 (2010). doi:10.1038/nrd3268 The new President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation discusses how his experience of leading Wyeth Vaccines will help the organization to reach its goal. more
The Salk inactivated poliovirus vaccine is one of the most rapid examples of bench‐to‐bedside translation in medicine. In the span of 6 years, the key basic lab discoveries facilitating the development of the vaccine were made, optimization and safety testing was completed in both animals and human more
Are you looking for influenza vaccine market data - answers to benefit your work? Our new report shows you revenue prospects for the manufacture and sale of influenza vaccines from 2009 to 2021. There, you will see commercial opportunities for influenza vaccines - original research, data and opini more
Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now. What revenues will biopharmaceutical markets achieve fro more
What will this decade hold for the challenged anti-obesity drug industry and market? Our new report gives you revenue forecasts at world, product and national level. We provide original research, data and opinions to benefit your work. By ordering now, you can stay ahead. We aim to save you time a more
Contact | FAQ | Site Map About – Vision – Management – The Board – Pharmaceutical Partners – Investors – Business Strategy – Corporate Governance – Company FAQ – Contact LNA Drug Platform – Drug Discovery Engine – microRNA – mRNA – Publications Product Pipeline – Drug Candidates Intellectual Pro more
Skip to the content Circassia Holdings Ltd Controlling the Immune System Home People Portfolio Partners News Contact People Circassia boasts a management team of experienced managers with an outstanding track record in the industry. The team combines strong development experience with proven commerc more
FAQs Brochure Home Latest News! NiKem Research Receives Authorization for Rodent Toxicology Studies (May 3rd, 2010) NiKem Research is pleased to announce that it has received on March 29th 2010, from the Italian Ministry of Health (Decree N. 69/2010-B), the authorization to perform acute and sub-chr more
Watchlist
This is where you can add this topic to your personal favourites
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
